Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Manufacturing (cGMP) deviations

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards.

1,754 FDA drug recalls with this cause, newest first.

This category covers departures from current Good Manufacturing Practice during production. It is FDA's broadest label, used when a facility's own process control failed somewhere along the line even if no single ingredient was proven unsafe on its own. Where the report names a specific consequence - a temperature excursion, a contaminant, a potency problem - we file the recall under that more specific cause instead; what remains here is the genuinely general case.

Class II · Moderate risk

Sn-d

Lack of Processing Controls.

Terminated cGMP deviation Synthetopes Inc D-1403-2019
Class II · Moderate risk

Pentreotide

Lack of Processing Controls.

Terminated cGMP deviation Synthetopes Inc D-1399-2019
Class II · Moderate risk

Unison Hand Care Products

CGMP Deviations: hand sanitizers and soaps were not produced under current good manufacturing practices.

Terminated cGMP deviation Inopak Ltd D-1319-2019
Class II · Moderate risk

Antibacterial Hand Soap

CGMP Deviations: hand sanitizers and soaps were not produced under current good manufacturing practices.

Terminated cGMP deviation Inopak Ltd D-1318-2019
Class II · Moderate risk

Antibacterial Hand Soap

CGMP Deviations: hand sanitizers and soaps were not produced under current good manufacturing practices.

Terminated cGMP deviation Inopak Ltd D-1315-2019
Class II · Moderate risk

INODERM Antiseptic Hand Soap

CGMP Deviations: hand sanitizers and soaps were not produced under current good manufacturing practices.

Terminated cGMP deviation Inopak Ltd D-1313-2019
Class II · Moderate risk

Cefdinir for Oral Suspension USP

CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.

Terminated cGMP deviation Lupin Pharmaceuticals Inc. NDC 68180-723-20 D-0376-2019
Class II · Moderate risk

Cefdinir for Oral Suspension USP

CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.

Terminated cGMP deviation Lupin Pharmaceuticals Inc. NDC 68180-722-20 D-0375-2019